Sumatriptan use in a large group-model health maintenance organization

American Journal of Health-System Pharmacy

Volumn 53, Issue 6, 1996, Pages 633-638

  Greiner, Deborah L ^a   Addy, Samuell N ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

Drug use; Health maintenance organizations; Migraine; Pharmacy, institutional; Protocols; Quality of life; Rational therapy; Serotonin agonists; Sumatriptan

Indexed keywords

ACETYLSALICYLIC ACID; BUTALBITAL; CAFERGOT; CAFFEINE; DICHLORALPHENAZONE; ISOMETHEPTENE; PARACETAMOL; PETHIDINE; PROPRANOLOL; SUMATRIPTAN;

ADOLESCENT; ADULT; ARTICLE; DRUG EFFICACY; DRUG FORMULARY; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SENSORY DYSFUNCTION; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX DISEASE; VERTIGO;

EID: 0029987939     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.6.633     Document Type: Article

References (17)

1. Stewart WF, Lipton RB, Celentano DD et al. Prevalence of migraine headache in the United States. JAMA. 1992; 267:64-9.
2. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992; 2:67-76.
3. Clouse JQ Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother. 1994; 28:659-64.
4. Barton CW. Evaluation and treatment of headache patients in the emergency department: a survey. Headache. 1994; 34:91-4.
5. Cady RK, Wendt JK, Kirchner JR et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991; 265:2831-5.
6. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991; 325:316-21.
7. Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol. 1991; 31:323-31.
8. Hsu VD. Sumatriptan: a new drug for vascular headache. Clin Pharm. 1992; 11:919-29.
9. Fullerton T, Gengo FM. Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother. 1992; 26:800-8.
10. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994; 47:622-51.
11. Ware JE Jr. SF-36 Health Survey manual and interpretation guide. Boston: Nimrod; 1993.
12. Kozma CM, Reeder CE, Lingle EW. Using repeated measures designs to evaluate interventions: a multivariate approach. J Res Pharm Econ. 1990; 2:55-73.
13. Johnson RA, Wichern DW. Applied multivariate statistical analysis. 2nd ed. Englewood Cliffs, NJ: Prentice-Hall; 1988.
14. Dahlöf C, Ekbom K, Persson L. Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache. Arch Neurol. 1994;51:1256-61.
15. Cerenex Pharmaceuticals. Imitrex package insert. Research Triangle Park, NC; 1994 May.
16. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993; 33:29-35
17. Greiner D. Outcomes evaluation for a new migraine agent: experience in an outpatient setting. Paper presented at Academy of Managed Care Pharmacy Meeting. Boston, MA; 1994 May 13.